Form 4 Filing for Cadrenal Therapeutics, Inc.

On June 22, 2026, and June 23, 2026, Pham Quang X, Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., sold a total of 11,444 shares of the company's common stock. The sales were conducted under a Rule 10b5-1 trading arrangement. The first transaction involved 9,167 shares sold at a weighted average price of $3.55, with prices ranging from $3.51 to $3.62. The second transaction involved 2,277 shares sold at a weighted average price of $3.20, with prices ranging from $3.20 to $3.22. Following these transactions, Mr. Pham directly owns 117,145 shares. Additionally, Mr. Pham, as Trustee of The PVBQ Living Trust, has voting and dispositive power over 200,000 shares held by the trust, of which his child is the sole beneficiary. The filing is a Form 4, indicating a change in beneficial ownership.